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Abstract
Background: Endothelial progenitor cells (EPCs) contribute to tumor angiogenesis and growth. We aimed to
determine whether inhibitors of differentiation 1 (Id1) were expressed in circulating EPCs of patients with ovarian
cancer, whether Id1 could mediate EPCs mobilization and recruitment, and, if so, what underlying signaling
pathway it used.
Methods: Circulating EPCs cultures were from 25 patients with ovarian cancer and 20 healthy control subjects. Id1
and integrin a4 expression were analyzed by real-time reverse transcription-polymerase chain reaction and western
blot. EPCs proliferation, migration, and adhesion were detected by MTT, transwell chamber, and EPCs-matrigel
adhesion assays. Double-stranded DNA containing the interference sequences were synthesized according to the
structure of a pGCSIL-GFP viral vector and then inserted into a linearized vector. Positive clones were identified as
lentiviral vectors that expressed human Id1 short hairpin RNA (shRNA).
Results: Id1 and integrin a4 expression were increased in EPCs freshly isolated from ovarian cancer patients
compared to those obtained from healthy subjects. siRNA-mediated Id1 downregulation substantially reduced EPCs
function and integrin a4 expression. Importantly, Inhibition of PI3K/Akt inhibited Id1 and integrin a4 expression,
resulting in the decreasing biological function of EPCs.
Conclusions: Id1 induced EPCs mobilization and recruitment is mediated chiefly by the PI3K/Akt signaling pathway
and is associated with activation of integrin a4.
Background
Numerous studies have indicated that angiogenesis, a
process mediated by endothelial progenitor cells (EPCs)
derived from the bone marrow, is increased in many
tumors due to elevated levels of angiogenic factors in
the peripheral blood. An increase in EPCs supply and
mobilization from the bone marrow can accelerate
tumor angiogenesis [1-3]. A number of reports have
described the incorporation of EPCs into tumor vessels
in both tumor models and human patients. However the
mechanisms that govern the behavior of EPCs, from
their origin in the BM to their release into the circula-
tion in response to pro-angiogenic stimuli, are still
poorly understood [4,5].
Id1 is a member of a family of 4 proteins (Id1-4)
known to inhibit the activity of basic helix loop helix
transcription factors by blocking their ability to bind
DNA [6]. Loss of Id1 in the BM leads to a complete
loss of EPCs in peripheral blood, which has been corre-
lated with a block in tumor neovascularization and
delayed tumor growth [7]. However, the actual role of
Id1 in regulating EPCs mobilization or recruitment
remains unknown. Given the key roles that EPCs migra-
tion and adhesion may play in tumor metastasis, we
tried to investigate the effect of Id1 on circulating EPCs
mobilization and recruitment and the possible signal
transduction pathways involved in the process.
We knocked down the expression of Id1 by an siRNA-
mediated Id1 lentiviral construct to determine the
functional importance of Id1 in EPCs of patients with
ovarian cancer,. Our results indicate that Id1 contributes
to the migration and adhesion of EPCs in ovarian cancer
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patients and that Id1 may be important in the pathogen-
esis of ovarian cancer. Next, we evaluated the effects of
inhibiting the phosphatidylinositol 3-kinase (PI3K)/Akt
signaling pathway on Id1 and integrin a4 in EPCs of
patients with ovarian cancer.
The identification of Id1 as a common target gene in
EPCs migration and adhesion suggested that Id1 might
serve as a novel therapeutic target in ovarian cancer. Id1
is expressed in bone marrow-derived EPCs [8] and is
highly expressed in ovarian cancer cells [9,10]. Inhibiting
Id1 can therefore both disrupt ovarian cancer cells




This study was approved by the local ethics committee
in China and informed consent was obtained from all
study participants. Twenty-five patients (median age, 41
years old; age range, 21-59 years old) with histologically
proven ovarian cancer, including serous cancer (n = 14),
mucinous cancer (n = 7), and endometrioid cancer
(n = 4), were studied along with a control group of healthy
women (n = 20, age range, 18-35 years old). These
diagnosed ovarian cancer patients had no additional
malignant, inflammatory, or ischemic disease; wounds; or
ulcers that could influence the number of EPCs.
EPCs isolation and characterization
Total MNCs were isolated from 20 ml human peripheral
blood samples from ovarian cancer patients and healthy
women by density gradient centrifugation with Histopa-
que-1077 (density 1.077 g/ml; Sigma). MNCs were pla-
ted in 1 ml endothelial growth medium (EGM-2; Lonza)
on fibronectin-coated (Sigma) twenty-four-well plates.
After 24 h of culturing, unattached cells were discarded
and attached cells were cultured as before. Medium was
replaced every 2 days thereafter, and each colony/cluster
was followed up. After 7 days in culture, colony forming
cells were recognized as attached spindle-shaped cells.
The adherent cells were incubated with DiI-acLDL
(Molecule Probes) and then fixed in 2% paraformalde-
hyde and counterstained with fluorescein isothiocyanate
(FITC)-labeled lectin from ulex europaeus agglutinin
(UEA-1) (Sigma). The fluorescent images were recorded
under a fluorescent microscope. Cells were also charac-
terized by immunofluorescence staining for von Willeb-
rand factor (vWF) and expression of CD31 and VEGFR2
(Becton Dickinson).
Quantitative real-time RT-PCR
Total RNA isolation and cDNA synthesis from cultured
EPCs were performed using Trizol and the SuperScript
II Reverse Transcriptase kit (Invitrogen, USA) according
to the manufacturer’s instructions.
Real-time PCR was performed with the Mx3000p Real
Time PCR System (Stratagene, USA) using the following
thermal cycling conditions: 10 sec at 95°C followed by
40 cycles of 15 sec at 95°C, 20 sec at 60°C, and 7 sec at
72°C. SYBR® GreenER qPCR SuperMix Universal S
(Invitrogen, USA) (25 μl) were performed in triplicate.
A no-template control (replacing RNA with water) was
used as a negative control. Id1 and integrin a4 mRNA
in the EPCs was determined by relative quantitation,
interpolating from a standard curve of template DNA of
known concentration and then normalized using b-actin
as an internal control. Data were analyzed by 2-ΔΔCt.








The EPCs were collected with sample buffer. Cell lysates
were centrifuged at 10000 g for 10 min at 4°C and the
supernatant was stored at -70°C. Protein concentrations
were determined with a Bio-Rad kit. 50-μg aliquots of
protein were subjected to 12% and 6% SDS-PAGE gels.
Then the protein was blotted onto a PVDF membrane.
Primary antibodies against Id1(1:1000, Becton Dickin-
son), integrin a4 (1:1000, Becton Dickinson), Phospho-
Akt (ser473) (1:1000, Cell Signaling), Total-Akt (1:2000,
Cell Signaling), and b-actin (1:2000, Becton Dickinson)
were used according to the manufacturer’s recommen-
dations. After washing the membrane, a second antibody
(HRP-conjugated anti-mouse IgG) (1:2000, Becton Dick-
inson) was used to detect Id1, integrin a4, Phospho-
Akt, Total-Akt, and b-actin. The bands were visualized
using the ECL detection system (Pierce) with 5 to
30 min exposure after washing the membrane. b-actin
were used as protein loading controls.
Construction of lentiviral vector expressing Id1-specific
shRNA
Three different Id1-specific target sequences were cho-
sen according to online siRNA tools provided by Invi-
trogen (http://www.invitrogen.com/rnai) using the Id1
reference sequence (Gene Bank Accession No
NM_002165). Double-stranded DNA containing the
interference sequences were synthesized according to
the structure of a pGCSIL-GFP viral vector (Gikai gene
company, Shanghai, China) and then inserted into a lin-
earized vector. All the constructs were cloned and
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sequenced to confirm their structure. The positive
clones were identified as lentiviral vectors that expressed
human Id1 short hairpin RNA (shRNA), hereafter desig-
nated pGCSIL/Id1-1, pGCSIL/Id1-2, and pGCSIL/Id1-3.
The three lentiviral vectors were transfected into HEK
293 cells separately to evaluate their RNA interference
effects and pGCSIL/Id1-3 (sequence: 5’-gaCAT-
GAACGGCTGTTACTCA-3’) induced the highest levels
of downregulation. So pGCSIL/Id1-3 vector and viral
packaging system (Gikai gene company, Shanghai,
China, containing an optimized mixture of two packa-
ging plasmids: pHelper 1.0 vector and pHelper 2.0 vec-
tor) were cotransfected into 293 cells to replicate
competent lentivirus. Viral supernatant was harvested
48 h after transfection, filtered through a 0.45-mm cellu-
lose acetate filter and frozen at -70°C. The lentivirus
(LV) containing the human Id1 shRNA-expressing cas-
sette (pGCSIL/Id1-3) was used as a positive control for
lentivirus production and denoted as Id1-RNAi-LV in
the next experiments. The pGCSIL/U6 mock vector was
also packaged and used as a negative control, denoted
as NC-GFP-LV. Viral concentrations were determined
by serial dilutions of the concentrated vector stocks in
293 cells in 96-well plates. The number of green fluores-
cent protein (GFP)-positive cells was measured 4 d
post-transduction under microscopy. The titers averaged
2 × 109 TU/mL.
In vitro transduction of EPCs
For lentiviral transduction, the primary EPCs were pas-
saged into 6-well plates at a density of 1 × 105 cells/
well. When cells reached 30% confluence (typically on
the third day after subculturing) the medium was
replaced with 1 mL of fresh medium containing lenti-
virus at an MOI of 150 and 6 μg/mL polybrene (Gikai
gene company, Shanghai, China). The medium was
replaced with fresh medium on the following day. Five
days after transduction cells were analyzed by flow cyto-
metry using a BD FACSCalibur cell analyzer (BD Bios-
ciences). The percentage of GFP-positive cells and mean
fluorescence intensity (MFI) of GFP-positive cells were
determined with WinMDI 2.8 software (J. Trotter, Flow
Cytometry Core Facility, Scripps Research Institute,
La Jolla, CA). Means and standard deviations from
experiments performed in triplicate are given.
Proliferation assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used to determine EPCs pro-
liferation. EPCs were incubated with 50-400 μg/ml
AGE-albumin or 400 μg/ml unmodified albumin for 24
h, then supplemented with MTT (0.5 mg/ml, Sigma)
and incubated for a further 4 h. The blue formazan thus
produced was solubilized with dimethyl sulfoxide and
absorbance was measured at 550-650 nm.
Transwell Migration Assay
After 7 days of incubation, culture medium was
removed and replaced with EBM-2 without any supple-
ment 12 hours before the migration assay. EPCs migra-
tion was evaluated using a transwell migration assay.
Briefly, 5 × 104 cells were suspended in 100 μL of
EBM-2 supplemented with 0.1% BSA and placed in the
upper chamber of an 8.0-mm pore size transwell
(Costar, Cambridge, MA). 600 μL of the final dilution
was placed in the lower chamber. After incubation for 6
hours at 37°C in 5% CO2, the cells that had not
migrated were removed from the upper surface of the
filters using cotton swabs and those that migrated to
the lower surface of the filters were fixed in methanol
and stained with Giemsa’s Stain Solution. Migration was
determined by counting the cell number with a micro-
scope. Five visual fields were randomly chosen for each
assay. The average number of the migrating cells in
these 5 fields was taken as the cell migration number of
the group.
Adhesion assay
EPCs were labeled with 4, 6-diamidino-2-phenylindole
(Roche Applied Science, Indianapolis, IN). After detach-
ment and centrifugation, EPCs were resuspended in
adhesion buffer (0.5% bovine serum albumin in EBM-2)
and identical numbers of cells were replated in fibronec-
tin-coated 24-well culture plates, incubated for 60 min
at 37°C, and then washed 3 times gently with adhesion
buffer to remove the nonadherent cells. The adherent
cells were counted by fluorescence microscopy at × 200
magnification. Five independent fields were assessed for
each well, and the average number of adherent cells per
× 200 field was determined.
To evaluate the ability of EPCs to adhere to conflu-
ent vascular endothelial cells, human vascular
endothelial cells were cultured in 1640 medium con-
taining 10% fetal bovine serum (Gibco) and served as
a matrix for the adhesion assay. Briefly, a monolayer
of vascular endothelial cells was prepared in 24-well
culture plates 48 h before the assay. EPCs were labeled
with 5, 6-carboxyfluorescein diacetate, succinimidyl
ester (CFSE). Finally, EPCs were added to each well
and incubated for 3 h at 37°C. Nonattached cells were
gently removed with PBS and adherent cells were
fixed with 4% paraformaldehyde and counted in five
random fields under 200 × magnification. The results
obtained revealed essentially unchanged results during
a 4-week observational period with a variation coeffi-
cient less than 6%.
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Statistical analysis
Statistical analyses were performed with Statistical Pack-
age for Social Sciences 13.0 software program (SPSS,
USA). The Mann-Whitney U test and Student’s t-test
were used to compare variables between the two groups.
Multiple comparisons were analyzed by Anova followed
by post-hoc analysis to adjust the significance level.
Data are shown as means ± S.E. Statistical significance
was considered as P < 0.05.
Results
Characterization of EPCs
After 7 days of culture, ex vivo expanded EPCs derived
from peripheral blood of healthy human volunteers and
ovarian cancer patients exhibited spindle-shaped mor-
phology. EPCs were characterized as adherent and dou-
ble positive for Dil-Ac-LDL uptake and lectin binding
based on their appearance in a fluorescent microscope.
A total of 93.8 ± 4.5% of adherent cells showed uptake
of Dil-Ac-LDL and lectin binding after 7 days of culture
in our study. The endothelial phenotype of these
expanded EPCs was further characterized by the expres-
sion of endothelial markers such as von willebrand fac-
tor, CD31, and VEGFR2. Immunofluorescence showed
that the cells were positive for vWF, CD31, and
VEGFR2 (Figure. 1).
Id1-RNAi-LV transfection inhibited the expression of Id1
mRNA and protein in EPCs
We used real-time RT-PCR to examine mRNA expres-
sion of Id1 in EPCs of 25 patients with ovarian cancer,
and Western blot analysis revealed a higher Id1 protein
expression in human ovarian cancer EPCs than in 20
healthy controls. To confirm the role of Id1 in EPCs of
patients with ovarian cancer we performed gene-silen-
cing experiments. EPCs were transfected with lentiviral-
Id1-siRNA vector. The negative control containing
pGCSIL/U6 mock vector only was denoted NC-GFP-LV.
After the Id1-RNAi-LV construct was transfected into
EPCs of 6 patients with ovarian cancer, Id1 mRNA
expression levels in transfected cells were compared to
those in nontransfected and control-transfected (NC-
GFP-LV) EPCs of 6 patients with ovarian cancer by
quantitative RT-PCR. Cells with Id1-RNAi-LV transfec-
tion showed a 72% reduction in the level of Id1mRNA
expression (Figure 2A). To further confirm the specifi-
city of Id1-RNAi-LV-mediated Id1 silencing, Id1 protein
expression was determined by Western blot. As shown
in Figure 2B-C, Id1 protein expression in EPCs of 6
patients with ovarian cancer transfected with Id1-RNA-
LV was significantly decreased compared to that in
control EPCs. These results indicate that lentivirus-
mediated RNAi was an effective way of modulating Id1
expression in cultured EPCs.
Effects of Id1-RNAi-LV on EPCs proliferation, migration
and adhesion
To examine EPCs functions in ovarian cancer we exam-
ined the proliferation, migration, and adhesion of EPCs.
Proliferation, migration, and adhesion of EPCs are
important for mobilization and recruitment. The EPCs
of ovarian cancer patients showed increased migration
and adhesion to fibronectin and endothelial cells.
Figure 1 Phenotypic characterization of EPCs from human
peripheral blood. After a week in culture, EPCs were stained with
DIL-labeled ac-LDL, FITC-conjugated Ulex europaeus lectin and
double stained with DIL-labeled ac-LDL and FITC-conjugated Ulex
europaeus lectin (overlay). von Willebrand factor (vWF), VEGFR2,
CD31 and double stained with VEGFR2 and CD31 (overlay) analysis
were assessed by immunofluorescence (× 20).
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Statistical analyses revealed that ovarian cancer
enhanced EPCs proliferation, migration, and adhesion.
After the Id1-RNAi-LV construct was transfected into
EPCs, the cells were cultured for 7 days and we then per-
formed EPCs proliferation, migration, and adhesion ana-
lysis. Id1-RNAi-LV markedly reduced EPCs functions.
Cells transfected with Id1-RNAi-LV displayed less prolif-
eration, migration, and adhesion abilities compared to
non-transfected control cells, as shown in Figure 3A-D.
Cells transfected with NC-GFP-LV, on the other hand,
exhibited no change in cell proliferation, migration, and
adhesion abilities, compared to non-transfected control
EPCs. These data indicate that Id1 is crucial for the
mobilization and recruitment of EPCs in ovarian cancer.
Id1-RNAi-LV transfection inhibited the expression of
integrin a4 mRNA and protein in EPCs
To explain the effect of Id1 on migration toward periph-
eral blood and recruitment to tumor tissues we explored
the expression of integrin a4 on the EPCs surface of 25
patients with ovarian cancer. In keeping with the mRNA
results, Western blots showed increased integrin a4 pro-
tein expression in EPCs.
After the Id1-RNAi-LV construct was transfected
into EPCs of 6 patients with ovarian cancer, integrin
a4 mRNA expression levels in transfected cells were
compared to those in nontransfected and control-
transfected (NC-GFP-LV) EPCs of 6 patients with
ovarian cancer by quantitative RT-PCR. Cells with Id1-
RNAi-LV transfection showed a 65% reduction in
integrin a4 mRNA expression (Figure 2A). Integrin a4
protein expression was then determined by Western
blot. As shown in Figure 2B, integrin a4 protein
expression in EPCs transfected with Id1-RNA-LV was
significantly decreased compared to that in control
EPCs. These results indicate that the effect of Id1 on
adhesion and angiogenesis is associated with activation
of integrin a4.
Figure 2 Id1-RNAi-LV transfection silenced the mRNA and protein expression of Id1 and integrin a4 in EPCs. (A) Id1 and integrin a4
mRNA expression by real-time RT-PCR. Data are expressed as means ± S.E. **p < 0.01 vs control, #p < 0.05 vs ovarian cancer. (B) Typical Western
blot images showing protein expression of Id1 and integrin a4 (b-actin is shown as a housekeeping control). (C) The graph showing the relative
Id1 and integrin a4 protein levels normalized to b-actin. The results were expressed as the mean ± S.E. **p < 0.01 vs. control, #p < 0.05 vs.
ovarian cancer.
Su et al. BMC Cancer 2010, 10:459
http://www.biomedcentral.com/1471-2407/10/459
Page 5 of 9
Effects of PI3K/Akt on Id1, integrin a4, and EPCs
functions
EPCs use a broad spectrum of mobilization and recruit-
ment mechanisms to achieve with enhanced tumor
metastasis (Shaked et al. 2006). To begin to determine
which signaling transduction pathways might participate
in Id1-mediated cell mobilization and recruitment in
EPCs, we investigated PI3K/AKT pathway using phar-
macological inhibitors. Elevated AKT-Ser473 phosphory-
lation was observed in EPCs, and it was completely
abolished by LY294002 (1 μmol/L). As Figure 4A-B
shows, Id1 and integrin a4 expression were also strongly
decreased by LY294002. Figure 3A-D show that EPCs of
patients with ovarian cancer had increased levels of cell
proliferation, migration and adhesion, which were
strongly decreased by incubation with LY294002. These
results indicate that Id1-induced EPCs mobilization and
recruitment is mediated by the PI3K/AKT pathway.
Thus Id1 induced migration and adhesion of EPCs is
mediated by an increase in integrin a4 expression and is
regulated by the PI3K/Akt pathway.
Discussion
Ovarian cancer is one of the most aggressive gynecologi-
cal malignancies and its high mortality is most often a
direct result of delays in diagnosis. Only 25% of ovarian
cancers are diagnosed while the malignancy is still con-
fined to the ovary, and the cure rate in these patients
can reach 90%. The remaining 75% of ovarian tumors
have spread beyond the ovary by the time of diagnosis
and the cure rate for these patients is less than 20%
[11]. With the advent of molecular-targeted therapies,
treatment for ovarian cancer is now moving beyond
conventional chemotherapy. Inhibition of the specific
Figure 3 Effects of Id1-RNAi-LV and LY294002 on EPCs proliferation, migration, and adhesion functions. (A) Typical images of migration
and adhesion as measured by transwell chamber and ECMatrix gel assay, respectively. (B) Effects of Id1-RNAi-LV and LY294002 on EPCs
proliferation. **p<0.01 vs. control, #,$p<0.05 vs. ovarian cancer. (C-D) Accumulated data showing EPCs migration and adhesion functions. *p<0.05,
**p<0.01 vs. control, #,$p<0.05 vs. ovarian cancer.
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cytokines essential for tumor vascularization is such a
therapy [12]. Thus anti-angiogenesis therapy has become
a new strategy for ovarian cancer treatment [13].
Evidence continues to accumulate confirming the
importance of EPCs in the neovascularization of tumor tis-
sues. Many researchers have focused on EPCs biology and
potential clinical applications [14-16]. Previous studies
have suggested that bone marrow-derived EPCs can
migrate to tumor foci and promote tumor growth and
metastasis. However, the signals that mediate mobilization
and recruitment of these cells to tumors are not well
understood. We showed previously that EPCs numbers
are increased in ovarian cancer patients and EPCs num-
bers were related to tumor progression and angiogenesis.
Here, using blood samples from 25 ovarian cancer
patients, we demonstrated that Id1 is involved in enhan-
cing EPCs migration and adhesion. Id1 may mediate EPCs
mobilization and recruitment to ovarian cancer tissues.
We further explored the effect of Id1 and related signaling
pathways on EPCs of patients with ovarian cancer.
Id1 has been implicated in a variety of cellular pro-
cesses including cell growth, differentiation, angiogen-
esis, and neoplastic transformation. Id1 is expressed in
various tumor tissues and cells [17]. Id1 knockout mice
were critical in demonstrating that BM-derived progeni-
tors are the source of tumor endothelium in some
tumor types and grades, as Id1 knockout mice failed to
mobilize these progenitors and transplantation of Id1
knockout mice with wild type BM was shown to rescue
the observed vascular defects [8,18]. The importance of
Id1+ progenitor cells in vascular rebound was confirmed
recently by results from vascular disrupting therapies
[19]. The mechanism by which Id1 controls the genera-
tion of EPCs is also beginning to be explored. In recent
studies, Id1 was shown to be expressed in long term
repopulating hematopoietic stem cells (lin- Sca+ kit+
CD34-) in the BM and Id1 loss was shown to lead to an
upregulation of the expression of the cyclin-dependent
kinase inhibitor p21. The expression of p21 in turn
drives the stem cells towards a more committed myeloid
state, as assessed by gene expression profiling; this mye-
loid differentiation is associated with the depletion of
cells capable of endothelial cell fate commitment
[20,21]. These results suggest that Id1 is required in
early hematopoietic stem cells to restrain the commit-
ment to the myeloid lineage and preserve a pool of cells
that give rise to endothelial progenitors in response to
vasculogenic growth signals. Although Id1 and Id3 are
thought to be functionally redundant in many cell types
[1,22]. It is not yet known if this is the case in EPCs.
In this study we show an essential role for Id1 in
EPCs mobilization and recruitment to the tumor. Our
real-time RT-PCR analysis indicates that Id1 expression
in ovarian cancer is significantly increased compared to
that in healthy subjects. Importantly, EPCs isolated from
ovarian cancer patients display increased integrin a4
expression and baseline migration and adhesion. This is
interesting in light of a recent report showing that integ-
rin a4 promotes the homing of circulating progenitor
cells and other bone marrow-derived mononuclear cir-
culating cells not only to tumor tissues but also to
inflamed and ischemic tissues [23]. To determine the
role of Id1 in EPCs, we repressed its expression. As
expected, transfection of EPCs with Id1-special siRNA
silenced Id1 expression and abolished upregulation of
integrin a4. Furthermore, migration and adhesion were
both inhibited in EPCs when they were transduced with
Id1-RNAi-LV. This indicates that Id1 is important for
EPCs migration and adhesion. Our data demonstrate
that down-regulation of Id1 may reduce the expression
of integrin a4, thereby contributing to the functional
inhibition we observed in our study.
Figure 4 Effects of PI3K/Akt on the protein expression of Id1,
integrin a4, p-Akt in EPCs. (A) Typical Western blot images
showing protein expression of Id1, integrin a4, p-Akt and t-Akt (b-
actin is shown as a housekeeping control). (B) The graph showing
the relative Id1, integrin a4, and p-Akt protein levels normalized to
actin. The results are expressed as the mean ± S.E. *p < 0.05 vs.
control, #,$p < 0.05 vs. ovarian cancer.
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Little is known about the molecular signaling path-
ways underlying EPCs mobilization and recruitment,
particularly in ovarian cancer patients. It has been
shown that Id1 is an important regulator for the fate of
hematopoietic stem cells. In this study, we showed that
high Id1 in EPCs is mediated by the PI3K/Akt pathway,
a key pathway in mediating vasculogenesis. We also
demonstrated that ovarian cancer activated the PI3K/
Akt signaling pathway in EPCs. This is a novel finding.
Therefore, we concluded that signaling through the
P13K/Akt signaling pathway upregulates Id1, which
enhances mobilization and recruitment via integrin a4.
We showed that Akt is phosphorylated in EPCs of ovar-
ian cancer patients, and inhibition of PI3K/Akt downre-
gulated the expression level of Id1 and integrin a4 and
reduced EPCs functions. Taken together, our data sup-
port the notion that ovarian cancer EPCs migration and
recruitment via the PI3K/Akt-Id1- integrin a4 signaling
pathway may be responsible for increased EPCs levels in
ovarian cancer.
Conclusions
We showed that Id1 induced proliferation, migration
and adhesion of human EPCs via the PI3K and Akt sig-
naling pathway. Our data also provide further insights
into the understanding of neovascularization. These
findings raise the possibility that therapeutic strategies
aiming to reduce EPCs angiogenesis have a two pronged
effect: they might enhance the efficacy of certain cyto-
toxic anti-angiogenesis ovarian cancer therapies while at
the same time reducing the risk of ovarian cancer
metastases.
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